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Abstract
Background: We assessed the rate of and predictors for all-cause mortality in patients with antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) receiving plasma exchange (PLEX) and evaluated the survival benefit of
PLEX for diffuse alveolar haemorrhage (DAH) between AAV patients receiving PLEX and those not receiving PLEX.
Methods: We retrospectively reviewed the medical records of 212 patients with AAV. Demographic, clinical and
laboratory data at the time of PLEX were collected from nine patients receiving PLEX, six of whom had DAH. The
follow-up duration was defined as the period from the time of PLEX or DAH occurrence to death for the deceased
patients and to the last visit for the survived patients.
Results: The median age of nine AAV patients receiving PLEX was 71.0 years, and five patients were men. Four of nine
patients receiving PLEX died at a median follow-up duration of 92.0 days. Three patients died of sepsis and one died
owing to a lack of response to PLEX. When patients with DAH receiving or not receiving PLEX were compared, there
were no significant differences in variables between the two groups. The cumulative patients’ survival rate between
patients with DAH receiving and not receiving PLEX were also compared using the Kaplan-Meier survival analysis;
however, no survival-benefit of PLEX for DAH was observed.
Conclusion: The rate of all-cause mortality in nine AAV patients receiving PLEX was found to be 44.4% and the notion
that PLEX is beneficial for the improvement in the prognosis of AAV-related DAH was deemed controversial.
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Background
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is one of the small vessel vasculitides
and comprises microscopic polyangiitis (MPA), granulo-
matosis with polyangiitis (GPA) and eosinophilic granu-
lomatosis with polyangiitis (EGPA) [1, 2]. The latest
recommendations for the management of AAV were
proposed by the European League Against Rheumatism
(EULAR) and the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA) in
2016 (the 2016 EULAR/ERA-EDTA recommendations)
[3]. According to these recommendations, a combination
of glucocorticoid with either cyclophosphamide (CYC)
or rituximab (RTX) should be administered to patients
newly diagnosed with life-threatening AAV. Once remis-
sion is achieved, azathioprine, methotrexate or RTX
could be maintained and glucocorticoid may be tapered.
In particular, in cases of renal failure with rapidly pro-
gressive glomerulonephritis (RPGN) or diffuse alveolar
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haemorrhage (DAH), plasma exchange (PLEX) should
be considered [3]. In addition to the 2016 EULAR/ERA-
EDTA recommendations, the 2012 Kidney Disease: Im-
proving Global Outcomes (KDIGO) clinical practice
guideline for glomerulonephritis recommends PLEX for
patients with rapid and severe renal vasculitis and sus-
pected anti-glomerular basement membrane (anti-GBM)
glomerulonephritis [4]. Therefore, PLEX is not usually
prescribed but is strongly recommended for patients
with life-threatening AAV.
With regard to RPGN, the Methylprednisolone versus
Plasma Exchange (MEPEX) clinical trial compared the
efficacy of PLEX and methylprednisolone pulse therapy
in 137 AAV patients with serum creatinine > 5.8 mg/dL
and reported that PLEX for induction exhibited a higher
frequency of renal recovery [5]. In addition, another clin-
ical trial reported that PLEX had a preventive efficacy
against the exacerbation of renal dysfunction in AAV pa-
tients with serum creatinine < 5.7 mg/dL in GPA pa-
tients [6]. In contrast, a long-term observational clinical
study, PLEX was found to have no significant benefit in
AAV patients with serum creatinine > 5.7 mg/dL or on
dialysis [7]. Moreover, recently, the data from the Plasma
Exchange and Glucocorticoids for Treatment of Anti-
Neutrophil Cytoplasm Antibody (ANCA)-Associated
Vasculitis (PEXIVAS) clinical trial reported that PLEX
had no efficacy for reducing the risk of both end-stage
renal disease or death in 704 AAV patients [8]. With re-
gard to DAH, several case series reported the positive ef-
ficacy of PLEX on DAH [9, 10]. In particular, a
retrospective study including 20 AAV patients with
DAH reported that combination therapy with PLEX and
immunosuppressive drugs was beneficial for lung out-
comes [11]. In contrast, a retrospective cohort study
including 53 AAV patients with severe alveolar haemor-
rhage reported no significant difference in mortality
between the PLEX and non-PLEX groups [12]. There-
fore, the efficacy of PLEX in life-threatening AAV
remains controversial.
To date, there has been no study investigating the effi-
cacy of PLEX on life-threatening AAV, such as RPGN
and DAH, on a large number of patients, except for a
few case reports from Korea. Hence, in this study, we in-
vestigated two clinical implications of PLEX on life-
threatening AAV. First, we assessed the rate of and pre-
dictors for all-cause mortality in AAV patients receiving
PLEX. Second, we assessed the survival-benefit of PLEX
for DAH between AAV patients receiving PLEX and
those not receiving PLEX.
Methods
Patients
We reviewed the electronic medical records of 212 AAV
patients from the retrospective Severance Hospital
ANCA-associated VasculitidEs cohort and selected nine
AAV patients who had received PLEX for life-
threatening AAV-related clinical symptoms based on the
following inclusion and exclusion criteria: i) patients
who had been first classified as having AAV at the Div-
ision of Rheumatology, Department of Internal Medi-
cine, Yonsei University College of Medicine, Severance
Hospital, from October 2000 to March 2019; ii) patients
who fulfilled the 2007 European Medicines Agency algo-
rithm for AAV and polyarteritis nodosa (the 2007 EMA
algorithm) and the 2012 revised International Chapel
Hill Consensus Conference vasculitides definitions [1,
13]; iii) patients who had well-documented medical re-
cords with which clinical and laboratory data at diagno-
sis could be reviewed and Birmingham vasculitis activity
score (BVAS) version 3 and five-factor score (FFS) at the
time of diagnosis could be calculated [14, 15]; iv) pa-
tients who had the results of tests for myeloperoxidase
(MPO)-ANCA and proteinase 3 (PR3)-ANCA [16]. We
also selected four AAV patients, who had exhibited
DAH but not received PLEX, and compared their clin-
ical and laboratory data with those of six AAV patients,
who had exhibited DAH and received PLEX. This study
was approved by the Institutional Review Board of Sev-
erance Hospital (4–2017-0673), who waived the need for
patient written informed consent, as this was a retro-
spective study.
Clinical and laboratory data
Age and gender were recorded as demographic data at
PLEX. Variant type, ANCAs, BVAS, FFS and each clin-
ical manifestation at PLEX were assessed. Reasons for
PLEX were also investigated. Methylprednisolone pulse
therapy and the administration of immunosuppressive
drugs before and at or after PLEX were evaluated. All
immunosuppressive drugs that had been administered
before the initiation of PLEX were included in ‘Adminis-
tered immunosuppressive drugs before PLEX’ regardless
of induction or maintenance therapy. The follow-up
duration was defined as the period from the time of
PLEX for DAH, RPGN and cardiac tamponade to death
for the deceased patients and as that to the last visit for
the survived patients. For AAV patients with DAH not
receiving PLEX, the follow-up duration was defined as
the period from the time of detection of DAH to death
for the deceased patients and to the last visit for the sur-
vived patients. The rate and aetiology of all-cause mor-
tality were assessed.
Statistical analyses
All statistical analyses were conducted using SPSS (ver-
sion 23 for Windows; IBM Corp., Armonk, NY, USA).
Continuous variables were expressed as a median (inter-
quartile range (IQR)), and categorical variables were
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expressed as the number and percentage. The univari-
able Cox hazards model analysis was performed to ap-
propriately obtain the hazard ratios (HRs) of each
variable for all-cause mortality. Significant differences in
categorical variables between the two groups were ana-
lysed using the Chi-square and Fisher’s exact tests. Sig-
nificant differences in continuous variables between the
two groups were analysed using the Mann-Whitney test.
A comparison of the cumulative patients’ survival rate




Clinical and laboratory data are described in Table 1.
Nine of 212 AAV patients (4.3%) received PLEX for life-
threatening AAV. The median age was 71.0 years, and
five patients were men. Six patients were classified as
having MPA and three patients were done as GPA but
none as EGPA. ANCAs were detected in six patients;
however, anti-GBM was not found. The median BVAS
and FFS at PLEX were 20.0 and 3.0, respectively. FFP
was used in all patients and there were no PLEX-related
complications including bleeding. Five patients received
PLEX nine times, two patients received it six times and
two patients received it three times. Six patients received
PLEX for DAH, two for RPGN, and one for cardiac tam-
ponade. Methylprednisolone pulse therapy was per-
formed at PLEX for all nine patients. The most
commonly administered immunosuppressive drugs be-
fore and at or after PLEX were CYC and RTX respect-
ively. Four of nine patients receiving PLEX died at a
median follow-up duration of 92.0 days. Three patients
died of sepsis and one died owing to a lack of response
to PLEX. Three patients deceased patients with DAH
were all admitted to the intensive care unit (ICU) and
received ventilation care along with continuous renal re-
placement therapy in ICU.
Predictors for all-cause mortality in AAV patients
receiving PLEX
We assessed the predictive value of each variable
for all-cause mortality using the univariable Cox
hazards model analysis. MPO-ANCA exhibited a
high HR for all-cause mortality; however, it was not
statistically significant (HR 5.710, P = 0.143). In
addition, neither DAH nor RPGN was associated
with all-cause mortality. Among the immunosup-
pressive drugs administered during follow-up, RTX
exhibited a tendency to reduce the rate of all-cause
mortality; however, this result was not statistically
significant (HR 0.209, P = 0.177) (Table 2).
Comparison between patients with DAH receiving PLEX
and those not receiving
As shown in Table 3, we compared variables between
patients with DAH receiving PLEX and those not receiv-
ing PLEX. There were no significant differences in
demographic data, AAV variants, ANCAs, AAV-specific
indices and immunosuppressive drugs administered be-
tween the two groups. In addition, the follow-up dur-
ation and the rate of all-cause mortality did not differ
significantly. We also compared the cumulative patients’
survival rate between patients with DAH receiving PLEX
and those not receiving PLEX using the Kaplan-Meier
survival analysis to assess the survival-benefit of PLEX
for DAH. However, we found no significant difference
between the two groups, which suggested that PLEX had
no survival benefit for DAH in AAV patients (Fig. 1).
Discussion
In this study, we arrived at two conclusions regarding
the efficacy of PLEX on life-threatening AAV. Firstly, in
terms of the rate of and predictors for all-cause mortality
in AAV patients receiving PLEX, the rate of all-cause
mortality was found to be 44.4%; however, no significant
predictor for all-cause mortality was determined. In the
MEPEX trial, the rates of all-cause mortality at 3 and 12
months were 16 and 27%, respectively, in the PLEX
group, which is reflective of renal involvement as a ser-
ious manifestation in combination with a high risk of in-
fection owing to immunosuppressive therapy [5].
Meanwhile, the PEXIVAS trial included two groups: 352
patients in the PLEX group and 352 in the no PLEX
group based on glucocorticoid therapy. The rate of all-
cause mortality and end-stage renal disease (ESRD) oc-
currence was 28.4% in the PLEX group and 31.0% in the
no PLEX group. The HR of PLEX on all-cause mortality
compared to that of no PLEX was 0.87 (95% confidence
interval 0.58–1.29). Therefore, PLEX did not have any
influence on the rate of all-cause mortality or ESRD oc-
currence in AAV patients [8]. It could be assumed that
the very high mortality rate might interfere and offset
the statistical significance of predictors of all-cause mor-
tality after performing PLEX. In addition, this may have
two clinical meanings: first, the therapeutic efficacy of
PLEX might not be as high as was expected. Second, the
severity of AAV might exceed the therapeutic potential
of PLEX on AAV.
Secondly, we compared the survival-benefit of PLEX
for DAH between patients with DAH receiving PLEX
and those not receiving PLEX. Most previous studies on
the efficacy of PLEX were conducted in AAV patients
with kidney involvement. Two representative clinical tri-
als, such as MEPEX and PEXIVAS, reported the conflict-
ing efficacy of PLEX on RPGN [5, 8]. As for AAV
patients with reduced kidney function due to RPGN,
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there are alternative treatment-modalities in addition to
PLEX: transient renal replacement together with com-
bination therapy comprising a high dose glucocorticoid
and either CYC or RTX may improve RPGN [3, 4].
However, as for patients with DAH, there is no alterna-
tive treatment-modality in addition to PLEX because
DAH is more rapidly progressive and fatal than RPGN.
Therefore, it seems impossible to design and conduct
randomised case-controlled clinical trials in AAV pa-
tients with urgent DAH, unlike that with RPGN.
There was an observational case series investigating
the efficacy of PLEX on DAH in 12 AAV patients who
were admitted to ICU. The authors demonstrated that
PLEX together with a combination of glucocorticoid and
immunosuppressive drugs might have a benefit to im-
prove both the respiratory dysfunction and AAV-related
DAH in AAV patients, although one patient died. In this
study, 10 AAV patients with DAH, of whom six patients
received PLEX, were retrospectively analysed [10]. How-
ever, unlike this previous study, our current study did
not find any efficacy of PLEX for DAH with regard to
the improvement of all-cause mortality. We considered
the follow-up period as the reason for this discrepancy.
The previous study evaluated the SpO2/FiO2 ratio and
assessed the mechanical ventilation mode hourly for 7
days. However, they did not evaluate all-cause mortality
after extubation and during follow-up [10]. Thus, it
could not be easily accepted that PLEX is beneficial for
the improvement in the prognosis of AAV-related DAH.
In contrast, the median follow-up duration of our study
was significantly longer than that of the previous study
(1145.5 days for four patients not receiving PLEX and
130.0 days for six patients receiving PLEX). Of the four
deceased AAV patients with DAH, three patients died of
Table 1 Characteristics of 9 patients with AAV at the time of
PLEX
Variables Values
Demographic data at PLEX
Age (years) 71.0 (25.0)
Male gender (N, (%)) 5 (55.6)




Gap-time from diagnosis to PLEX (days) 69.0 (127.0)
ANCA and anti-GBM within 4 weeks before PLEX (N, (%))
MPO-ANCA 4 (44.4)
PR3-ANCA 2 (22.2)
ANCA negativity 3 (33.3)
Anti-GBM 0 (0)
AAV related indices at PLEX
BVAS 20.0 (14.0)
FFS 3.0 (1.5)
Clinical manifestations at PLEX (N, (%))
General 9 (100)
Cutaneous 1 (11.1)






Nervous systemic 2 (22.2)
Reason for PLEX (N, (%))
DAH 6 (66.6)
RPGN 2 (22.2)
Pericarditis with cardiac tamponade 1 (11.1)
Methylprednisolone pulse therapy at PLEX (N, (%)) 9 (100)

















Follow-up duration (days) 92.0 (225.5)
All-cause mortality (N, (%)) 4 (44.4)
Cause of death (N, (%)) (N = 4)
Sepsis 3 (75.5)
No response to PLEX 1 (25.5)
Values are expressed as median (interquartile range (IQR)) or
number (percentage)
ANCA antineutrophil cytoplasmic antibody, AAV antineutrophil cytoplasmic
antibody-associated vasculitis, PLEX plasma exchange, MPA microscopic
polyangiitis, GPA granulomatosis with polyangiitis, EGPA eosinophilic GPA;
MPO: myeloperoxidase, PR3 proteinase 3, GBM glomerular basement
membrane, BVAS Birmingham vasculitis activity score, FFS five factor score, ENT
ear nose throat, DAH diffuse alveolar haemorrhage, RPGN rapidly progressive
glomerulonephritis, CYC cyclophosphamide, RTX rituximab, AZA azathioprine,
MMF mycophenolate mofetil, TAC tacrolimus
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sepsis due to secondary pneumonia and one patient died
because of the rapid progression of DAH owing to the
ineffectiveness of PLEX (Table 3).
Considering the results of both our study and previous
studies, we would suggest the use of therapeutic strat-
egies depending on the time-course. Firstly, within 1 or
2 weeks from DAH development, PLEX along with com-
bination comprising glucocorticoid with CYC or RTX
should be promptly initiated under close observation in
the intensive care unit. This strategy is expected to re-
duce the rate of all-cause mortality from 8.3 to 10.0%.
Next, after 2 weeks from DAH development, the most
common reason for death was secondary pneumonia
and sepsis. Therefore, the monitoring of pneumonia oc-
currence, the use of preventive antibiotics and the choice
of dose or type of immunosuppressive drugs should be
carefully considered.
Our study has several limitations. Firstly, we provided
a narrative report rather than an analytical one as the
number of patients who received PLEX was too small to
conduct a subgroup analysis. In particular, for this rea-
son, we realise that the reliability of the Cox propor-
tional analysis of this study might be limited and low.
Secondly, we could not obtain sufficient information
from the medical record such as PLEX technique, venti-
lator modes and lung-involvement pattern owing to the
Table 2 Univariable Cox hazards model analysis of variables for all-cause mortality
Variables HR 95% CI P value
Demographic data at PLEX
Age 1.007 0.952, 1.064 0.820
Male gender 1.330 0.186, 9.528 0.777
AAV variants 0.016 0.000, 60.511 0.327
ANCA within 4 weeks before PLEX
MPO-ANCA 5.710 0.556, 58.595 0.143
PR3-ANCA 0.027 0.000, 231.881 0.434
ANCA negativity 0.676 0.069, 6.581 0.736
AAV related indices at PLEX
BVAS 0.940 0.800, 1.104 0.450
FFS 1.247 0.423, 3.678 0.689
Clinical manifestations at PLEX
General N/A
Cutaneous 0.041 0.000, 5,961,414.0 0.739
Mucous membrane/Eyes N/A
ENT 0.024 0.000, 119.450 0.391
Pulmonary 1.008 0.103, 9.837 0.995
Cardiovascular 0.491 0.050, 4.786 0.540
Abdominal N/A
Renal 0.649 0.067, 6.322 0.710
Nervous systemic 0.993 0.102, 9.69. 0.995
Reason for PLEX
DAH vs. RPGN 1.544 0.139, 17.193 0.724
Administered immunosuppressant drugs during follow-up
CYC 1.893 0.194, 18.490 0.583
RTX 0.209 0.022, 2.024 0.177
AZA 7.483 0.467, 119.824 0.155
MMF 0.038 0.000, 5830.207 0.592
TAC N/A
None 1.541 0.158, 15.021 0.710
PLEX plasma exchange, ANCA antineutrophil cytoplasmic antibody, AAV antineutrophil cytoplasmic antibody-associated vasculitis, MPO myeloperoxidase, PR3
proteinase 3, BVAS Birmingham vasculitis activity score, FFS five factor score, ENT ear nose throat, DAH diffuse alveolar haemorrhage, RPGN rapidly progressive
glomerulonephritis, CYC cyclophosphamide, RTX rituximab, AZA azathioprine, MMF mycophenolate mofetil, TAC tacrolimus
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Table 3 Comparison of variables between patients with DAH receiving PLEX and those not receiving
Variables Patients with DAH not receiving PLEX (N = 4) Patients with DAH receiving PLEX (N = 6) P value
Demographic data at DAH
Age (years) 56.5 (21.0) 65.5 (34.0) 0.807
Male gender (N, (%)) 2 (50.0) 3 (50.0) 1.000
MPA vs. GPA (N, (%)) 3 (75.0) 4 (66.7) 0.778
ANCA within 4 weeks before DAH (N, (%))
MPO-ANCA 3 (75.0) 2 (33.3) 0.197
PR3-ANCA 1 (25.0) 2 (33.3) 0.778
ANCA negativity 0 (0) 2 (33.3) 0197
AAV related indices at DAH
BVAS 16.0 (17.0) 15.0 (13.5) 1.000
FFS 2.0 (0) 2.5 (2.25) 1.000
Steroid pulse at DHA (N, (%)) 4 (100) 6 (100) N/A
Administered immunosuppressive drugs (N, (%))
CYC 4 (100) 5 (83.3) 0.389
RTX 0 (0) 2 (33.3) 0.197
AZA 3 (75.0) 1 (16.7) 0.065
MMF 0 (0) 2 (33.3) 0.197
TAC 0 (0) 1 (16.7) 0.389
None 0 (0) 1 (16.7) 0.389
Follow-up duration (days) 1145.5 (3421.5) 130.0 (291.8) 0.080
All-cause mortality (N, (%)) 1 (25.0) 3 (50.0) 0.429
Values are expressed as median (interquartile range (IQR)) or number (percentage)
DAH diffuse alveolar haemorrhage, PLEX plasma exchange, MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, ANCA antineutrophil cytoplasmic
antibody, MPO myeloperoxidase, PR3 proteinase 3, AAV antineutrophil cytoplasmic antibody-associated vasculitis, BVAS Birmingham vasculitis activity score, FFS
five factor score, CYC cyclophosphamide, RTX rituximab, AZA azathioprine, MMF mycophenolate mofetil, TAC tacrolimus
Fig. 1 Comparison of the cumulative patients’ survival rate between patients with DAH receiving PLEX and those not receiving PLEX. No
significant difference was observed between the two groups, which suggest that PLEX had no survival benefit for DAH in AAV patients. DAH:
diffuse alveolar haemorrhage; PLEX: plasma exchange; AAV: antineutrophil cytoplasmic antibody-associated vasculitis
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limitation of the retrospective study design. Thirdly, this
study analysed data that had been accumulated over 8
years. During this period, the considerable improvement
has taken place not only in the overall prognosis of AAV
patients but also in the accuracy of ANCA tests and the
efficacy of immunosuppressive drugs. Therefore, this
might influence the results of this retrospective and ob-
servational study. Despite these limitations, we believe
that our study, which is based on the largest cohort in
Korea, could provide valuable information on PLEX in
Korean patients with AAV. Therefore, this study has
clinical significance as a pilot study.
Conclusions
Nine of 212 AAV patients (4.3%) received PLEX and the
rate of all-cause mortality in nine AAV patients receiv-
ing PLEX was found to be 44.4%. DAH was the most
common reason for using PLEX; however, the notion
that PLEX is beneficial for the improvement in the prog-
nosis of AAV-related DAH was deemed controversial.
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